Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2018

View Archived Issues

Chemical changes make arylomycins great against Gram-negatives

Zinc fingers go where CRISPR can't

Viva VIVO

White matter targeting improves TBI outcomes

Iterum announces the initiation of SURE 2 and SURE 3 phase III studies for sulopenem

Identification of a diagnostic gene signature in Kawasaki disease

Mechanisms of bacterial competition used by microbiota as a tool to develop new targeted antibiotics

Molecular Templates and Takeda enter agreement for joint development of CD38-targeted ETBs

Servier to use Poietis' 4D bioprinting technology for liver tissue

China Pharmaceutical University, Hefei Yigong Medicine describe new colchicine derivatives

Beijing Scitech-Mq Pharmaceuticals patents VEGFR-2 and HGFR inhibitors

Fujian Cosunter Pharmaceutical, Medshine Discovery divulge compounds for HBV infection

Neuronascent receives award to further develop NNI-362 for Alzheimer's

Apeiron Biologics and Lead Discovery Center to develop novel immune checkpoint modulators

Researchers present data for GSK-773 in myopathy

Preclinical profile of PI3K-delta inhibitor DS-1515 shows potential for treating asthma

Erytech begins phase III trial of eryaspase in second-line metastatic pancreatic cancer

Amygdala Neurosciences announces SEARCH phase II studies with ANS-6637

Oxurion initiates phase II study of THR-317 in macular telangiectasia type 1

Nanobiotix reports new data on NBTXR-3

Celltrion signs incubation agreement with Emory University to support atherosclerosis R&D

TAS-303 shows potential as a novel therapeutic agent for stress urinary incontinence

Mutations in ADPRHL2 linked to a degenerative pediatric stress-induced epileptic ataxia syndrome

RNF146 identified as novel therapeutic target in colorectal cancer

Immune system activation observed in phase I trial of AST-008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...